| Schick Technologies, Inc. | |||
| Ticker: | SCHK | 31-00 47th Avenue | |
| Exchange: | NASDAQ-National Market | Long Island City, NY 11101 | |
| Industry: | Manufacturing (SIC Code 3844) | (718) 937-5765 | |
| Type of Shares: | Common Shares | Filing Date: | 5/13/97 | |
| U.S. Shares: | 1,750,000 | Offer Date: | 6/30/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $15.00 - $17.00 | |
| Primary Shares: | 1,750,000 | Offer Price: | $18.50 | |
| Secondary Shares: | 0 | Gross Spread: | $1.29 | |
| Offering Amount: | $28,000,000 | Selling: | $0.74 | |
| Expenses: | - | Reallowance: | $0.10 | |
| Shares Out After: | 9,707,231 |
| Manager | Tier | Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 526-8100 |
| J.P. Morgan Securities Inc. | Co-manager | (212) 648-0517 |
| Pacific Crest Securities Inc. | Co-manager | (503) 790-0293 |
| Issuer's Law Firm: | Kelley Drye & Warren |
| Bank's Law Firm: | Chadbourne & Parke |
| Auditor: | Price Waterhouse |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 3/31/97 | 3/31/97 | ||||
| Revenue: | $16.10 | Assets: | $11.06 | ||
| Net Income: | -$0.35 | Curr Assets: | |||
| EPS: | -$0.04 | Liabilities: | $4.97 | ||
| Prior EPS: | -$0.02 | Curr Liabilities: | |||
| Cash Flow/Oper: | -$0.27 | Equity: | $6.09 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company designs, develops and manufactures innovative digital imaging systems and devices for the dental and medical markets. The company's products, which are based on proprietary digital imaging technologies, create instant high resolution radiographs with reduced levels of radiation. In the field of dentistry, the company has developed, and currently manufactures and markets, the leading intra-oral digital radiography system. The company has also developed an inexpensive and easy-to-use bone mineral density measurement device to assist in the diagnosis of osteoporosis. This device is scheduled for introduction in the second half of 1997, pending marketing clearance from the United States Food and Drug Administration, and will be sold for use in primary care physicians' offices. In addition, the company is developing large-area radiographic imaging devices for digital mammography. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to repay the principal of the Merck Loan and accrued interest, expand its research and development capabilities, expand its marketing and sales effort, working capital and general corporate purposes. |